Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Cogent Biosciences (COGT)

Cogent Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:COGT
DateTimeSourceHeadlineSymbolCompany
09/12/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
09/12/202412:00GlobeNewswire Inc.Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis PatientsNASDAQ:COGTCogent Biosciences Inc
08/12/202417:00GlobeNewswire Inc.Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)NASDAQ:COGTCogent Biosciences Inc
14/11/202421:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:COGTCogent Biosciences Inc
14/11/202417:24Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:COGTCogent Biosciences Inc
12/11/202413:00GlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
05/11/202414:00GlobeNewswire Inc.Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) MeetingNASDAQ:COGTCogent Biosciences Inc
23/10/202411:00GlobeNewswire Inc.Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer TherapeuticsNASDAQ:COGTCogent Biosciences Inc
03/09/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
03/09/202412:00GlobeNewswire Inc.Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility AnalysisNASDAQ:COGTCogent Biosciences Inc
06/08/202420:53Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:COGTCogent Biosciences Inc
06/08/202412:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COGTCogent Biosciences Inc
06/08/202412:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
06/08/202412:00GlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
27/06/202412:00GlobeNewswire Inc.Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trialNASDAQ:COGTCogent Biosciences Inc
14/06/202411:30GlobeNewswire Inc.Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)NASDAQ:COGTCogent Biosciences Inc
13/06/202423:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
13/06/202423:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
13/06/202423:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
13/06/202423:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
13/06/202410:06Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:COGTCogent Biosciences Inc
13/06/202401:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
05/06/202420:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
29/05/202420:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
29/05/202420:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
23/05/202421:05GlobeNewswire Inc.Cogent Biosciences Appoints Cole Pinnow as Chief Commercial OfficerNASDAQ:COGTCogent Biosciences Inc
23/05/202421:01GlobeNewswire Inc.Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual MeetingNASDAQ:COGTCogent Biosciences Inc
07/05/202412:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COGTCogent Biosciences Inc
07/05/202412:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
07/05/202412:00GlobeNewswire Inc.Cogent Biosciences Reports First Quarter 2024 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:COGT